Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

TaiGen, YiChang HEC create JV in the Greater China region

Executive Summary

TaiGen Biotechnology Co. Ltd. and YiChang HEC ChangJiang Pharmaceutical Co. Ltd. have created a Chinese joint venture to develop, manufacture, and commercialize direct-acting antiviral agents (DAAs) for treating chronic hepatitis C virus (HCV) in mainland China, Taiwan, Hong Kong, and Macau.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Joint Venture
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register